Who are Angiomax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Revasc, Argatroban, Refludan, Lovenox (Preservative Free), Indion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bivalirudin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Angiomax — Competitive Intelligence Brief

Angiomax (BIVALIRUDIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-coagulant [EPC]. Area: Cardiovascular.

marketed Anti-coagulant [EPC] thrombin Cardiovascular Recombinant protein Live · refreshed every 30 min

Target snapshot

Angiomax (BIVALIRUDIN) — Novartis. Bivalirudin directly inhibits thrombin by binding to its catalytic site and anion-binding exosite, preventing thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Angiomax TARGET	BIVALIRUDIN	Novartis	marketed	Anti-coagulant [EPC]	thrombin	2000-01-01
Pradaxa	dabigatran-etexilate	Boehringer Ingelheim	marketed	Direct thrombin inhibitor	Thrombin (serine protease)	2010-01-01
Revasc	DESIRUDIN	Marathon Pharms Llc	marketed	Anti-coagulant	Prothrombin	2003-01-01
Argatroban	ARGATROBAN	Hikma Pharm Co Ltd	marketed	Anti-coagulant [EPC]	Prothrombin	2000-01-01
Refludan	LEPIRUDIN		marketed	Anti-coagulant	Prothrombin	1998-01-01
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	marketed	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
Indion	PHENINDIONE	Sanofi	marketed	phenindione	Prothrombin, Vitamin K epoxide reductase complex subunit 1, Arachidonate 5-lipoxygenase	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-08-31 — Pradaxa · 7866474 · US
2027-09-26 — Argatroban · 7687516 · Formulation · US
2027-09-26 — Argatroban · 7589106 · Formulation · US
2028-03-02 — Pradaxa · 7866474*PED · US
2031-01-20 — Pradaxa · 9034822 · US
2031-07-20 — Pradaxa · 9034822*PED · US

Sponsor landscape (Anti-coagulant [EPC] class)

· 1 drug in this class
CorMedix · 1 drug in this class
Hikma Pharm Co Ltd · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Angiomax — Competitive Intelligence Brief. https://druglandscape.com/ci/bivalirudin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab